Pharmacotherapy for obsessive-compulsive disorder (OCD): predicting response and moving beyond serotonin re-uptake inhibitors

Brakoulias, Vlasios; Tsalamanios, Emmanouil

doi:10.1080/14656566.2016.1250886

Cited by 8 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In phase Ib trials, tepotinib shows antitumor activity in Asian patients with advanced HCC, including patients with c-MET-positive tumors [ 42 ]. Currently, the single-arm phase II trials of tepotinib are continuing in Caucasian HCC patients who are c-MET-positive and sorafenib-insensitive [ 43 ]. Overall, tepotinib MSC2156119J shows antitumor activity in nonclinical studies and phase Ib trials in c-MET-positive HCC patients.…”

Section: Inhibitors Of C-met/hgf Signaling and Hepatocellular Carcmentioning

confidence: 99%

HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

Zhang

Feng

Chen

et al. 2018

IJMS

View full text Add to dashboard Cite

The HGF/c-MET pathway is active in the development of digestive system cancers, indicating that inhibition of HGF/c-MET signaling may have therapeutic potential. Various HGF/c-MET signaling inhibitors, mainly c-MET inhibitors, have been tested in clinical trials. The observed efficacy and adverse events of some c-MET inhibitors were not very suitable for treating digestive system cancers. The development of new HGF/c-MET inhibitors in preclinical studies may bring promising treatments and synergistic combination (traditional anticancer drugs and c-MET inhibitors) strategies provided anacceptable safety and tolerability. Insights into miRNA biology and miRNA therapeutics have made miRNAs attractive tools to inhibit HGF/c-MET signaling. Recent reports show that several microRNAs participate in inhibiting HGF/c-MET signaling networks through antagonizing c-MET or HGF in digestive system cancers, and the miRNAs-HGF/c-MET axis plays crucial and novel roles for cancer treatment. In the current review, we will discuss recent findings about inhibitors of HGF/c-MET signaling in treating digestive system cancers, and how miRNAs regulate digestive system cancers via mediating HGF/c-MET pathway.

show abstract

Section: Inhibitors Of C-met/hgf Signaling and Hepatocellular Carcmentioning

confidence: 99%

HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

Zhang

Feng

Chen

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Oral cGVHD manifests in 45–83% of transplant patients, and the most important clinical manifestations are represented by lichenoid oral mucositis, Sjögren-like signs, and scleroderma. In particular, with regard to lichenoid changes, they are frequently localized in the labial and buccal mucosa, the tongue, and the palate with different clinical aspects—atrophic, erythematous, erosive, ulcerative, keratotic reticular-, or plaque-type—with or without pain [ 9 , 10 , 11 ]. Furthermore, in patients with oral cGVHD, there is a greater incidence of pyogenic granuloma, verruciform xanthoma, and oral squamous cell carcinoma (OSCC) [ 5 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Oral Dysplastic Complications after HSCT: Single Case Series of Multidisciplinary Evaluation of 80 Patients

Leuci

Coppola

Blasi

et al. 2020

Life

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is the most common secondary solid malignancy after hematopoietic stem-cell transplantation (HSCT). OSCC following HSCT is frequently preceded by chronic graft-versus-host disease (cGVHD). The aim of this study was to describe a cohort of post-HSCT patients and to evaluate the onset of oral epithelial dysplasia and/or OSCC over time. In this retrospective cohort study, we present a cohort of hematological patients that underwent HSCT. Demographic variables, clinical hematological data, data regarding acute graft-versus-host disease (aGVHD) and cGVHD, and oral clinical features were analyzed. We focused on clinicopathological features of a subgroup of 22 patients with oral cGVHD and OSCC after HSCT. Among 80 included patients, 46 patients (57.5%) developed aGVHD and 39 patients (48.7%) developed cGVHD. Oral mucosa was involved in 17 patients with aGVHD (36.9%) and in 22 patients (56.4%) with cGVHD. Out of a total of 22 oral biopsies, roughly 40% revealed mild to moderate dysplasia, and 32% were OSCC. In the absence of international agreement on the best timing of oral follow-up after HSCT, it is mandatory to establish a close multidisciplinary evaluation in order to prevent the onset of HSCT-related OSCC and to reduce post-transplant mortality due to secondary tumors.

show abstract

“…This condition affects 1%-3% of the general population worldwide (2-4); however, in an Iranian survey, its prevalence was reported to be 5.1%(5). OCD is also a disabling psychiatric disease (6), with remission rate of 10% after standard pharmacological treatment (7).…”

Section: Introductionmentioning

confidence: 99%

Raphe nuclei echogenicity changes in obsessive-compulsive disorder

Mohammadzade

Shalbafan

Shariat

et al. 2018

Med. J. Islam. Repub. Iran

View full text Add to dashboard Cite

Background: Dysregulation of serotonin system is hypothesized to play the main role in the etiology of obsessive-compulsive disorder (OCD). Transcranial sonography (TCS) is a helpful noninvasive and low-cost tool for the assessment of subcortical brain architectures, mainly basal nuclei, cerebellar central structures, and midbrain. In this study, an ultrasound assessment was performed for a sample of the patients with OCD and healthy control group to evaluate echogenicity of midbrain raphe nuclei (RN). Methods: A total of 35 patients with OCD and 35 healthy controls of similar age and sex entered the study. Semi-structured clinical interview was performed according to the DSM IV-TR criteria to verify OCD. Echogenicity of the midbrain RN was assessed by an experienced neurologist applying TCS. The echogenicity of the 2 groups was compared using chi- square test. SPSS software (version 18, PASW) was used for statistical analysis and p-value of less than 0.05 was considered significant. Results: In this study, 15 OCD patients (42.9%) and 11 (31.4%) controls showed decreased echogenicity of midbrain RN. Also, the results of the chi-square test showed that the midbrain RN echogenicity was not significantly lower in patients with OCD compared to the control group (p= 0.322). Conclusion: Although decreased midbrain RN echogenicity is a characteristic of patients with major depression, it was not shown in OCD patients in this study, which can be explained by the involvement of RN projections rather that RN serotoninergic neurons.

show abstract

Pharmacotherapy for obsessive-compulsive disorder (OCD): predicting response and moving beyond serotonin re-uptake inhibitors

Cited by 8 publications

References 16 publications

HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

Oral Dysplastic Complications after HSCT: Single Case Series of Multidisciplinary Evaluation of 80 Patients

Raphe nuclei echogenicity changes in obsessive-compulsive disorder

Contact Info

Product

Resources

About